Literature DB >> 21247362

Treating tension-type headache -- an expert opinion.

Lars Bendtsen1, Rigmor Jensen.   

Abstract

INTRODUCTION: Tension-type headache (TTH) is a highly prevalent disorder with enormous costs for the individual and the society. AREAS COVERED: Nonpharmacological and pharmacological treatments are reviewed. Electromyographic (EMG) biofeedback has a documented effect in TTH, while cognitive-behavioral therapy and relaxation training are most likely to be effective. Physical therapy and acupuncture may be valuable options for patients with frequent TTH. Simple analgesics and nonsteroidal anti-inflammatory drugs are recommended for treatment of episodic TTH. Combination analgesics containing caffeine are drugs of second choice. Triptans, muscle relaxants and opioids should not be used. It is crucial to avoid frequent and excessive use of analgesics to prevent the development of medication-overuse headache. The tricyclic antidepressant amitriptyline is the drug of first choice for the prophylactic treatment of chronic TTH. Mirtazapine and venlafaxine are second-choice drugs. EXPERT OPINION: There is an urgent need for more research in nonpharmacological as well as pharmacological treatment possibilities of TTH. Future studies should examine the relative efficacy of the various treatment modalities and clarify how treatment programs can be optimized and combined to best suit the individual patient. Frequent TTH may be difficult to treat, but an acceptable result can usually be obtained by a combination of nonpharmacological and pharmacological treatments.
© 2011 Informa UK, Ltd

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247362     DOI: 10.1517/14656566.2011.548806

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

1.  Chinese Herbal Formula Xuefu Zhuyu for Tension-Type Headache with Qi-Stagnation and Blood-Stasis Pattern (CheruXTH): Study Protocol for a Randomized Controlled Trial.

Authors:  Li Zhou; Zhe Zhang; Geng Li; Shaojun Liao; Hongfei Zhou; Pengqin Wang; Guanghui Liu; Li Bai; Zehuai Wen
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-11       Impact factor: 2.629

Review 2.  Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence.

Authors:  Alejandro Labastida-Ramírez; Silvia Benemei; Maria Albanese; Antonina D'Amico; Giovanni Grillo; Oxana Grosu; Devrimsel Harika Ertem; Jasper Mecklenburg; Elena Petrovna Fedorova; Pavel Řehulka; Francesca Schiano di Cola; Javier Trigo Lopez; Nina Vashchenko; Antoinette MaassenVanDenBrink; Paolo Martelletti
Journal:  J Headache Pain       Date:  2020-05-24       Impact factor: 7.277

3.  Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020.

Authors:  Henrik W Schytz; Faisal M Amin; Rigmor H Jensen; Louise Carlsen; Stine Maarbjerg; Nunu Lund; Karen Aegidius; Lise L Thomsen; Flemming W Bach; Dagmar Beier; Hanne Johansen; Jakob M Hansen; Helge Kasch; Signe B Munksgaard; Lars Poulsen; Per Schmidt Sørensen; Peter T Schmidt-Hansen; Vlasta V Cvetkovic; Messoud Ashina; Lars Bendtsen
Journal:  J Headache Pain       Date:  2021-04-08       Impact factor: 7.277

Review 4.  Orofacial pain management: current perspectives.

Authors:  Marcela Romero-Reyes; James M Uyanik
Journal:  J Pain Res       Date:  2014-02-21       Impact factor: 3.133

5.  The challenge of managing headache disorders in a tertiary referral neurology clinic in Rwanda.

Authors:  Celestin Kaputu-Kalala-Malu; Timothy D Walker; Olga Ntumba-Tshitenge; Eric M Mafuta; Pierrot L Tugirimana; Jean P Misson
Journal:  Neurosciences (Riyadh)       Date:  2016-04       Impact factor: 0.906

6.  Migraine, tension-type headache and medication-overuse headache in a large population of shift working nurses: a cross-sectional study in Norway.

Authors:  Bjørn Bjorvatn; Ståle Pallesen; Bente E Moen; Siri Waage; Espen Saxhaug Kristoffersen
Journal:  BMJ Open       Date:  2018-11-18       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.